What Causes Barrett's Esophagus?
Barrett's esophagus develops from chronic acid and bile exposure, damaging the normal esophageal lining. Repeated injury triggers a cellular transformation where normal squamous cells are replaced by more acid-resistant intestinal-type cells. While this represents an adaptive response, the transformed cells carry a significantly higher risk of malignant transformation.
Who Is at Risk?
- Long-standing GERD symptoms lasting more than 5 years
- Male sex: Barrett's esophagus is two to three times more common in men
- Age over 50
- Central obesity and smoking
- Family history of Barrett's esophagus or esophageal adenocarcinoma
- Presence of a hiatus hernia
What Are the Symptoms of Barrett's Esophagus?
Barrett's esophagus causes no distinctive symptoms beyond underlying GERD. Some patients paradoxically report reduced heartburn as metaplasia develops due to decreased pain sensitivity of the changed lining. The absence of distinctive symptoms means Barrett's esophagus cannot be diagnosed from symptoms alone and requires upper endoscopy with biopsy for confirmation.
How Is Barrett's Esophagus Diagnosed?
Upper Endoscopy and Biopsy
Upper endoscopy is used as the gold standard in diagnosing Barrett's esophagus. During an upper endoscopy, the gastroenterologist searches for the "salmon pink" color of Barrett's mucosa, which usually replaces the normal "pale pink" color of the esophagus. The presence of intestinal metaplasia or "goblet cells" is confirmed by biopsy.
The length of the Barrett's segment is classified as:
- Short-segment: Less than 3 cm in length
- Long-segment: 3 cm or more in length
Long-segment Barrett's carries a higher cancer risk than short-segment disease.
Who Should Be Screened?
According to the ACG (2022), endoscopic screening is recommended for men aged 50 or over with chronic GERD symptoms (more than 5 years) and at least two additional risk factors, including central obesity, smoking, or family history.
What Is Dysplasia in Barrett's Esophagus?
Dysplasia refers to precancerous cellular changes within Barrett's segment. Dysplasia grade directly affects the management of the patient:
- No dysplasia: The annual cancer risk is approximately 0.3 percent
- Low-grade dysplasia: The annual cancer risk is approximately 0.5 to 1 percent
- High-grade dysplasia: The annual cancer risk is approximately 5 to 10 percent
A repeat evaluation by a second pathologist should be considered for all cases of dysplasia, as this carries significant clinical implications.
How Is Barrett's Esophagus Monitored and Treated?
Endoscopic Surveillance
Regular endoscopic surveillance detects dysplasia at an early treatable stage. ACG (2022) recommended surveillance intervals:
- No dysplasia: Endoscopy every 3 to 5 years
- Low-grade dysplasia: Endoscopy every 6 to 12 months or endoscopic eradication therapy
- High-grade dysplasia: Endoscopic eradication therapy rather than continued surveillance
Acid Suppression Therapy
Long-term PPI therapy reduces acid exposure to the Barrett's segment and may slow dysplasia progression. According to Gut (2014), PPI use is associated with significantly reduced dysplasia and cancer progression risk in Barrett's esophagus patients.
Endoscopic Eradication Therapy
Radiofrequency Ablation (RFA)
RFA is the gold standard endoscopic treatment for dysplastic Barrett's esophagus. Controlled heat energy destroys abnormal Barrett's tissue while preserving the underlying esophageal structure. Normal squamous epithelium regenerates under continued PPI therapy. According to the NEJM (2009), RFA achieves complete dysplasia eradication in approximately 90 percent of patients.
Endoscopic Mucosal Resection (EMR)
EMR removes visible nodules or raised areas within the Barrett's segment containing early cancer or high-grade dysplasia.This is often used in conjunction with RFA for the residual flat Barrett's esophagus following nodule removal.
Conclusion
Barrett's esophagus is the most important long-term GERD complication and the primary pathway through which GERD leads to esophageal cancer. Early identification through screening, consistent PPI therapy, regular surveillance endoscopy, and timely endoscopic eradication of dysplasia are the most effective strategies for preventing esophageal adenocarcinoma.
If you have had long-standing GERD symptoms without endoscopic evaluation, discuss Barrett's esophagus screening with your gastroenterologist without delay.
